Table 3.

List of clinical trials in melanoma combining the current therapies with epigenetic modifiers.

Disease	Phase	Therapy	Status	NCT ID
Metastatic melanoma	I	Panobinostat, temozolomide, and decitabine	Safe combination To be continued in a phase II trial	NCT00925132
Stage III and IV melanoma	I	ACY-241 with ipilimumab and nivolumab	Completed	NCT02935790
Metastatic melanoma	II	Entinostat	Completed	NCT00185302
Metastatic uveal melanoma	II	Entinostat with pembrolizumab	Active, not recruiting	NCT02697630
Metastatic melanoma	I	Panobinostat	Completed	NCT01065467
Metastatic melanoma	II	Vorinostat	Side effects, early responses, partial response in two patients and stable disease in most [156]	NCT00121225
Stage III/IV melanoma	I	Panobinostat in combination with ipilimumab	Most patients had serious adverse events	NCT02032810
Malignant melanoma	I	Tinostamustine	Recruiting	NCT03903458
Stage III/IV melanoma	Ib	Mocetinostat in combination with ipilimumab and nivolumab	Terminated	NCT03565406
Metastatic uveal melanoma	II	Entinostat in combination with pembrolizumab	Manageable toxicity, tumor regression, and durable responses	NCT02697630
Stage III/IV melanoma	I	Decitabine	Completed	NCT00002980
Stage III/IV melanoma	I	Decitabine	Completed	NCT00030615
Metastatic melanoma	II	Azacitidine in combination with pembrolizumab	Recruiting	NCT02816021